$ELOS B #Elos Medtech AB Elos Medtech - ’20 remains difficult, but long-term story intact: Q2’20 sales -36%, but EBIT only down 5% ’20 estimates: Sales -4%, EBIT +11% on a higher margin Increased value range: SEK 56-95 https://t.co/o0k3DXX8DW #equity #stocks https://t.co/sRwzT4kD1u